The European Commission recently awarded Cergentis a €1.2 million grant to support the development of its TLA technology for use in FFPE samples.
The Fix-C method is a modified version of Hi-C and makes use of the fact that the structural information relevant in cancer is preserved in FFPE samples.
UK researchers have dug into the archive to find more cancer samples for sequencing, Nature News reports.
The company plans to outlicense the assay, developed using a custom Affymetrix microarray, to an interested partner.
Two researchers devised a protocol to sequence DNA from ancient samples and tested it on 100-year-old museum specimens.
The combination of the new test with Biocartis' existing KRAS assay offers customers a complete solution for testing metastatic colorectal cancers as reccomended by professional guidelines.
The company plans to raise $25 million in a Series B financing round. It is also working on a two-color chemistry and aims to develop an instrument for clinical applications.
The diagnostic, a real-time PCR kit for breast cancer stratification, is being reviewed under a special process for the approval of innovative products.
Earlier this month at AGBT, company researchers presented the new developments, which Thermo Fisher plans to roll out later this year.
They plan to combine Silicon’s DEPArray digital-sorting technology with Macrogen’s NGS systems to develop genomic tests for different cancers.
Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.
The Wall Street Journal looks into the cost of new gene therapies.
An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.
In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.